Myokines as biomarkers of frailty and cardiovascular disease risk in females.

Abstract

Frailty is a risk factor for cardiovascular disease (CVD). Biomarkers have the potential to detect the early stages of frailty, such as pre-frailty. Myokines may act as biomarkers of frailty-related disease progression, as a decline in muscle health is a hallmark of the frailty phenotype. This study is a secondary analysis of 104 females 55years of age or older with no previous history of CVD. Differences in systemic myokine concentrations based on frailty status and CVD risk profile were examined using a case-control design. Propensity matching identified two sets of 26 pairs with pre-frailty as the exposure variable in low or elevated CVD risk groups for a total 104 female participants. Frailty was assessed using the Fried Criteria (FC) and CVD risk was assessed using the Framingham Risk Score (FRS). Factorial ANOVA compared the main effects of frailty, CVD risk, and their interaction on the concentrations of 15 myokines. Differences were found when comparing elevated CVD risk status with low for the concentrations of EPO (384.76±1046.07 vs. 206.63±284.61pg/mL, p=.001), FABP3 (2772.61±3297.86 vs. 1693.31±1019.34pg/mL, p=.017), FGF21 (193.17±521.09 vs. 70.18±139.51pg/mL, p=.010), IL-6 (1.73±4.97 vs. 0.52±0.89pg/mL, p=.023), and IL-15 (2.62±10.56 vs. 0.92±1.25pg/mL, p=.022). Pre-frail females had lower concentrations of fractalkine compared to robust (27.04±20.60 vs. 103.62±315.45pg/mL, p=.004). Interaction effects between frailty status and CVD risk for FGF21 and OSM were identified. In elevated CVD risk, pre-frail females, concentrations of FGF21 and OSM were lower than that of elevated CVD risk, robust females (69.10±62.86 vs. 317.24±719.69, p=.011; 1.73±2.32 vs. 24.43±69.21, p=.018, respectively). These data identified specific biomarkers of CVD risk and biomarkers of frailty that are exacerbated with CVD risk.